Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare ConferenceGlobeNewsWire • Monday
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business UpdateGlobeNewsWire • 11/05/26
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026GlobeNewsWire • 11/02/26
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy BodiesGlobeNewsWire • 10/22/26
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045GlobeNewsWire • 10/13/26
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLBGlobeNewsWire • 09/29/26
Cognition Therapeutics to Present at H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/08/26
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/07/26
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business UpdateGlobeNewsWire • 08/06/26
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision SummitGlobeNewsWire • 07/13/26
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks RemainSeeking Alpha • 06/26/26
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting MinutesGlobeNewsWire • 06/24/26
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045GlobeNewsWire • 06/16/26
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with PsychosisGlobeNewsWire • 05/21/26
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesGlobeNewsWire • 05/14/26
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business UpdateGlobeNewsWire • 05/07/26
Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development UpdateGlobeNewsWire • 03/26/26
Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial ResultsGlobeNewsWire • 03/23/26